journal article·2018-01-13Open access

Calcium Phosphates as Delivery Systems for Bisphosphonates

Adriana Bigi, Elisa Boanini

Abstract

Bisphosphonates (BPs) are the most utilized drugs for the treatment of osteoporosis, and are usefully employed also for other pathologies characterized by abnormally high bone resorption, including bone metastases. Due to the great affinity of these drugs for calcium ions, calcium phosphates are ideal delivery systems for local administration of BPs to bone, which is aimed to avoid/limit the undesirable side effects of their prolonged systemic use. Direct synthesis in aqueous medium and chemisorptions from solution are the two main routes proposed to synthesize BP functionalized calcium phosphates. The present review overviews the information acquired through the studies on the interaction between bisphosphonate molecules and calcium phosphates. Moreover, particular attention is addressed to some important recent achievements on the applications of BP functionalized calcium phosphates as biomaterials for bone substitution/repair.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Bone health and treatments · Bone Tissue Engineering Materials · Boron Compounds in Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry “G. Ciamician”, University of Bologna, 40126 Bologna, Italy

References (100+)

Show source-provided references
1. Aparicio, C., and Ginebra, M.P. (2015). Ion substitution in biological and synthetic apatites. Biomineralization and Biomaterials, Foundamentals and Applications, Woodhead Publishing (Imprint Elsevier).
2. A tissue engineering approach to bone repair in large animal models and in clinical practice10.1016/j.biomaterials.2007.06.023 ↗
3. In vitro degradation of calcium hosphates: Effect of multiscale porosity, textural properties and composition10.1016/j.actbio.2017.07.033 ↗
4. Functionalized biomimetic calcium phosphates for bone tissue repair
5. Bisphosphonates: The first 40 years10.1016/j.bone.2011.04.022 ↗
6. Biomedical applications of bisphosphonates10.1016/j.jconrel.2013.01.032 ↗
7. Therapeutic strategies for treating osteolytic bone metastases10.1016/j.drudis.2014.04.004 ↗
8. Long-term safety of bisphosphonates10.1210/jc.2005-0057 ↗
9. Is bisphosphonate therapy compromised by the emergence of adverse bone disorders?10.1016/j.drudis.2013.08.010 ↗
10. Bisphosphonates: Therapeutics potential and recent advances in drug delivery10.3109/10717544.2013.870259 ↗
11. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy10.1007/s00198-007-0540-8 ↗
12. Alendronate zwitterions bind to calcium cations arranged in columns10.1107/S0108270103025599 ↗
13. Alendronate hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells10.1016/j.biomaterials.2007.10.040 ↗
14. Differences between bisphosphonates in binding affinities for hydroxyapatite
15. Targeted delivery to bone and mineral deposits using bisphosphonate ligands10.1016/j.addr.2015.10.005 ↗
16. A computational model delineates differences in hydroxyapatite binding affinities of bisphosphonate
17. Biochemical and molecular mechanisms of action of bisphosphonates10.1016/j.bone.2010.11.008 ↗
18. Bisphosphonates in cancer therapy10.1016/j.canlet.2007.07.007 ↗
19. Coercing bisphosphonates to kill cancer cells with nanoscale coordination polymers10.1039/c2cc17635a ↗
20. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase10.1016/j.bone.2010.09.035 ↗
21. Vertebroplasty using bisphosphonate-loaded calcium phosphate cement in a standardized vertebral body bone defect in an osteoporotic sheep model10.1016/j.actbio.2014.07.012 ↗
22. The use of bisphosphonates in cancer treatment10.1111/j.1749-6632.2010.05766.x ↗
23. Potential anticancer properties of bisphosphonates10.1053/j.seminoncol.2010.06.008 ↗
24. Inhibition of osteoclast-like cell formation by bisphosphonates in long term cultures of human bone marrow10.1172/JCI114100 ↗
25. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro10.1172/JCI114459 ↗
26. Bisphosphonates act directly ion the osteoclast to induce caspase cleavage of MST 1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase10.1074/jbc.274.49.34967 ↗
27. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts10.1172/JCI116422 ↗
28. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don’t know10.1016/j.bone.2010.10.159 ↗
29. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability10.1016/j.bone.2010.08.008 ↗
30. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo10.1359/jbmr.080617 ↗
31. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review10.1016/j.bone.2013.09.023 ↗
32. Ten years’ experience with alendronate for osteoporosis in postmenopausal women10.1056/NEJMoa030897 ↗
33. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure10.1359/jbmr.070906 ↗
34. Bisphosphonates for Osteoporosis—Where do we go from here?10.1056/NEJMp1202619 ↗
36. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: An analysis of 31 cases with confocal laser scanning microscopy10.1016/j.bone.2009.05.008 ↗
37. Subtrochanteric fractures after long-term treatment with bisphosphonates: A European society on clinical and economic aspects of osteoporosis and osteoarthritis, and international osteoporosis foundation working group report10.1007/s00198-010-1453-5 ↗
38. Bisphosphonates for the prevention and treatment of osteoporosis10.1136/bmj.h3783 ↗
39. Safety of bisphosphonates10.1016/j.bone.2011.01.003 ↗
40. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors10.1016/j.bone.2013.08.007 ↗
41. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors10.1200/JCO.2005.04.2465 ↗
42. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort10.1002/jbmr.288 ↗
43. Micrometer-sized magnesium whitlockite crystals in micropetrosis of bisphosphonate-exposed human alveolar bone10.1021/acs.nanolett.7b02888 ↗
44. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure10.1002/adma.200602497 ↗
45. Time course of zoledronate interaction with hydroxyapatite nanocrystals10.1021/jp304472s ↗
46. Hydroxyapatite–alendronate composite systems for biocompatibile materials10.1007/s10973-016-5905-9 ↗
47. Salamanna, F., Giavaresi, G., Parrilli, A., Torricelli, P., Boanini, E., Bigi, A., and Fini, M. (2017). Antiresorptive properties of strontium substituted and alendronate functionalized hydroxyapatite nanocrystals in an ovariectomized rat spinal arthrodesis model. Mater. Sci. Eng. C, in press.
48. The effect of zoledronate-hydroxyapatite nanocomposites on osteoclasts and osteoblast-like cells in vitro10.1016/j.biomaterials.2011.09.092 ↗
49. Combined effect of strontium and zoledronate on hydroxyapatite structure and bone cell responses10.1016/j.biomaterials.2014.03.053 ↗
50. Strontium ranelate: A novel mode of action optimizing bone formation and resorption10.1007/s00198-004-1753-8 ↗
51. Quercetin and alendronate multi-functionalized materials as tools to hinder oxidative stress damage10.1002/jbm.a.36192 ↗
52. Antiresorptive and anti-angiogenetic octacalcium phosphate functionalized with bisphosphonates: An in vitro tri-culture study10.1016/j.actbio.2017.02.040 ↗
53. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite10.1016/j.bone.2005.05.003 ↗
54. Novel biomaterials for bisphosphonate delivery10.1016/j.biomaterials.2004.05.019 ↗
55. Reaction of zoledronate with β-tricalcium phosphate for the design of potential drug device combined systems10.1021/cm702584d ↗
56. Chemically modified calcium phosphates as novel materials for bisphosphonate delivery10.1002/adma.200306340 ↗
57. NMR investigations of the static and dynamic structures of bisphosphonates on human bone: A molecular model10.1021/ja0759949 ↗
58. Hybrid materials applied to biotechnologies: Coating of calcium phosphates for the design of implants active against bone resorption disorders10.1039/b503680a ↗
59. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro10.1002/jbm.a.31989 ↗
60. Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters10.1021/ml5004603 ↗
61. Interaction between a bisphosphonate, tiludronate, and biomimetic nanocrystalline apatites10.1021/la3046548 ↗
62. Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites10.1016/j.jcis.2014.01.017 ↗
63. Adsorption on apatitic calcium phosphates for drug delivery: Interaction with bisphosphonate molecules10.1007/s10856-014-5218-0 ↗
64. Hydroxyapatite functionalization to trigger adsorption and release of risedronate10.1016/j.colsurfb.2017.09.055 ↗
65. Novel therapeutic intervention for osteoporosis prepared with strontium hydroxyapatite and zoledronic acid: In vitro and pharmacodynamic evaluation10.1016/j.msec.2016.10.066 ↗
66. New processing approaches in calcium phosphate cements and their applications in regenerative medicine10.1016/j.actbio.2010.01.036 ↗
67. Calcium phosphate cements for bone substitution: Chemistry, handling and mechanical properties10.1016/j.actbio.2013.11.001 ↗
68. Next generation calcium phosphate-based biomaterials10.4012/dmj.28.1 ↗
69. Silicon-stabilized α-tricalcium phosphate and its use in a calcium phosphate cement: Characterization and cell response10.1016/j.actbio.2011.11.021 ↗
70. Self-setting calcium orthophosphate formulations10.3390/jfb4040209 ↗
71. Calcium phosphate-based cements: Clinical needs and recent progress10.1039/C2TB00061J ↗
72. Reactivity of calcium phosphate cements10.1039/b706411j ↗
73. Setting mechanism of a biomimetic bone cement10.1021/cm049363e ↗
74. Advantages of using glycolic acid as a retardant in a brushite forming cement10.1002/jbm.b.30830 ↗
75. High-strength resorbable brushite bone cement with controlled drug-releasing capabilities10.1016/j.actbio.2008.08.005 ↗
76. Optimization of a biomimetic bone cement: Role of DCPD10.1016/j.jinorgbio.2011.05.006 ↗
77. Dicalcium phosphate cements: Brushite and monetite10.1016/j.actbio.2011.08.005 ↗
78. Local drug delivery for enhancing fracture healing in osteoporotic bone10.1016/j.actbio.2014.09.006 ↗
79. Calcium phosphate cements as drug delivery materials10.1016/j.addr.2012.01.008 ↗
80. Alendronate and pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells10.1016/j.jinorgbio.2008.09.012 ↗
81. Investigation of alendronate-doped apatitic cements as a potential technology for the prevention of osteoporotic hip fractures: Critical influence of the drug introduction mode on the in vitro cement properties10.1016/j.actbio.2010.09.017 ↗
82. Evaluation of a novel osteoporotic drug delivery system in vitro: Alendronate-loaded calcium phosphate cement10.3928/01477447-20100625-15 ↗
83. Molecular mechanisms of crystallization impacting calcium phosphate cements10.1098/rsta.2010.0006 ↗
84. Microstructure and properties of alendronate-loaded calcium phosphate cement10.1016/j.msec.2014.05.043 ↗
85. Functionalization of biomimetic calcium phosphate bone cements with alendronate10.1016/j.jinorgbio.2010.06.008 ↗
86. In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite10.1016/j.biomaterials.2010.06.047 ↗
87. Spray-congealed solid lipid microparticles as a new tool for the controlled release of bisphosphonates from a calcium phosphate bone cement10.1016/j.ejpb.2017.10.002 ↗
88. Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement10.1002/jbm.a.30792 ↗
89. Bone formation on biomimetic calcium phosphate-coated and zoledronate-immobilized titanium implants in osteoporotic rat tibiae10.11607/jomi.3423 ↗
90. Alendronate-loaded hydroxyapatite-TiO2 nanotubes for improved bone formation in osteoporotic rabbits10.1039/C5TB01956G ↗
91. Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V10.1007/s10856-011-4524-z ↗
92. XPS and bioactivity study of the bisphosphonate pamidronate adsorbed onto plasma sprayed hydroxyapatite coatings10.1016/j.apsusc.2006.05.031 ↗
93. The inhibitory effect of alendronate-hydroxyapatite composite coating on wear debris-induced peri-implant high bone turnover10.1016/j.jss.2012.02.003 ↗
94. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats10.1016/j.biomaterials.2008.12.025 ↗
95. Hydroxyapatite nanocrystals functionalized with alendronate as bioactive components for bone implant coatings to decrease osteoclastic activity10.1016/j.apsusc.2014.12.072 ↗
96. Biofunctional alendronate-hydroxyapatite thin films deposited by Matrix Assisted Pulsed Laser Evaporation10.1016/j.biomaterials.2009.07.066 ↗
97. Strontium and zoledronate hydroxyapatites graded composite coatings for bone prostheses10.1016/j.jcis.2015.01.088 ↗
98. Biomimetic materials for tissue engineering10.1016/j.addr.2007.08.041 ↗
99. Biopolymer/calcium phosphate scaffolds for bone tissue engineering10.1002/adhm.201300562 ↗
100. Recent advances in bone tissue engineering scaffolds10.1016/j.tibtech.2012.07.005 ↗